Compass Therapeutics (CMPX) Cash & Equivalents: 2023-2025
Historic Cash & Equivalents for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $46.8 million.
- Compass Therapeutics' Cash & Equivalents rose 25.18% to $46.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.8 million, marking a year-over-year increase of 25.18%. This contributed to the annual value of $44.1 million for FY2024, which is 81.82% up from last year.
- Latest data reveals that Compass Therapeutics reported Cash & Equivalents of $46.8 million as of Q3 2025, which was up 99.71% from $23.4 million recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Cash & Equivalents registered a high of $46.8 million during Q3 2025, and its lowest value of $19.3 million during Q2 2023.
- In the last 3 years, Compass Therapeutics' Cash & Equivalents had a median value of $30.4 million in 2023 and averaged $32.5 million.
- Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 81.82% in 2024, then dropped by 4.29% in 2025.
- Compass Therapeutics' Cash & Equivalents (Quarterly) stood at $24.2 million in 2023, then surged by 81.82% to $44.1 million in 2024, then rose by 25.18% to $46.8 million in 2025.
- Its Cash & Equivalents stands at $46.8 million for Q3 2025, versus $23.4 million for Q2 2025 and $41.6 million for Q1 2025.